The takeout speculation prompted by Avanir Pharmaceuticals Inc.'s patent victory earlier in the year came to pass in the form of an agreement with Otsuka Pharmaceutical Co. Ltd. under which the Tokyo-based pharma will pay $17 per share in cash, or about $3.5 billion, in a deal expected to close in the first quarter of next year.